Researchers evaluated the safety of SER-109 and its effect on CDI recurrence among adult outpatients.
All articles by Dee Rapposelli
Researchers evaluated HRQOL outcomes among patients with a history of recurrent CDI who received either SER-109 or placebo.
Latest News Your top articles for MondayFor More Personalized News
Haymarket Medical NetworkTop Picks
Continuing Medical Education (CME/CE) Courses